The Department of Veterans Affairs National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Specgx LLC, doing business as Mallinckrodt Pharmaceuticals, for the supply of buprenorphine hydrochloride/naloxone hydrochloride sublingual tablets. The $28,220,287.65 contract has a period of performance from June 7, 2021 to June 6, 2022 with four one-year option periods. Specgx, a foreign-owned for-profit pharmaceutical manufacturer, will provide the tablets to the VA, Department of Defense, Bureau of Prisons, and Indian Health Service through the VA and DOD pharmaceutical prime vendor programs. The contract was awarded without any set-aside designations, reflecting the specialized nature of the products. The original solicitation 36E79721R0001 was issued by the VA National Acquisition Center seeking offers for these buprenorphine/naloxone tablets, with estimated annual requirements of 145,412 bottles of 2mg/0.5mg tablets and 275,699 bottles of 8mg/2mg tablets. This IDC award enables Specgx to provide a consistent supply of these critical pharmaceutical products to federal healthcare providers, supporting various medical treatments and research initiatives across multiple agencies.
Generated 1/15/25, 9:03 AM